Clinical Trials Logo

Atypical Teratoid/Rhabdoid Tumor clinical trials

View clinical trials related to Atypical Teratoid/Rhabdoid Tumor.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05952687 Withdrawn - Rhabdoid Tumor Clinical Trials

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Start date: March 2024
Phase: Phase 1
Study type: Interventional

iSTAR is an open-label, multi-center, phase 1b study of oral XPO1 inhibitor selinexor and oral MDM2 inhibitor idasanutlin in children with progressive or recurrent atypical teratoid/rhabdoid tumors (AT/RT), malignant rhabdoid tumors (MRT) and synchronous/metachronous rhabdoid tumors. Primary Objectives - To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of combination treatment with oral idasanutlin and selinexor in children with recurrent or progressive AT/RT or MRT. - To characterize the plasma pharmacokinetics of oral idasanutlin and selinexor in children with recurrent or progressive AT/RT or MRT, to assess potential covariates to explain the inter- and intra-individual pharmacokinetic variability. Secondary Objectives - Evaluate safety of the combination treatment with oral idasanutlin and selinexor in children - Evaluate efficacy of the combination treatment of idasanutlin and selinexor as measured by objective response (partial response [PR] or complete response [CR]) rate separately in progressive/relapsed AT/RT and progressive/relapsed MRT - Estimate progression-free and overall-survival separately in progressive/relapsed AT/RT and progressive/relapsed MRT

NCT ID: NCT04521946 Withdrawn - Malignant Glioma Clinical Trials

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Start date: January 14, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer. Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit anti-thymocyte globulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.